Drug:
Reaction: GENERAL PHYSICAL HEALTH DETERIORATION
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26499365 |
TR |
50 | 1 |
Multiple organ dysfunction syndrome, General physical health deterioration, Pyrexia, Fungal infection, |
||||
AMPHOTERICIN B, VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN, CEFEPIME HYDROCHLORIDE, CEFEPIME, FLUCYTOSINE, |
||||
| 302 | 26499591 |
EU |
64 | 1 |
General physical health deterioration, Cytokine release syndrome, |
||||
GLOFITAMAB, SULFAMETHOXAZOLE AND TRIMETHOPRIM, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, |
||||
| 303 | 26499691 |
OM |
51 | 2 |
General physical health deterioration, |
||||
RIBOCICLIB, |
||||
| 304 | 26499698 |
CA |
76 | 2 |
Blood cholesterol increased, Constipation, Decreased appetite, Diarrhoea, Dizziness, Drug effect less than expected, Fatigue, General physical health deterioration, Hepatic enzyme increased, Joint injury, Loss of consciousness, Nausea, Nervousness, Pyrexia, Rheumatoid arthritis, Somnolence, Weight decreased, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, DESOXIMETASONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, PREDNISONE, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 305 | 26499826 |
PK |
51 | 2 |
Breast cancer metastatic, General physical health deterioration, Pain, |
||||
TRASTUZUMAB, |
||||
| 306 | 26499885 |
CA |
59 | 2 |
Crohn^s disease, COVID-19, Sinusitis, General physical health deterioration, |
||||
INFLIXIMAB, |
||||
| 307 | 26500186 |
EU |
61 | 1 |
Malignant neoplasm progression, Haemoptysis, Obstructive airways disorder, Asthenia, General physical health deterioration, |
||||
PEMBROLIZUMAB, |
||||
| 308 | 26500634 |
EU |
86 | 2 |
Immunotoxicity, General physical health deterioration, |
||||
CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), DOSTARLIMAB, |
||||
| 309 | 26500939 |
US |
||
Lung disorder, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 310 | 26501060 |
US |
78 | |
Transfusion, General physical health deterioration, Intentional dose omission, |
||||
VUTRISIRAN, VUTRISIRAN, |
||||
| 311 | 26501153 |
65 | 2 | |
Fatigue, Cough, Cardiogenic shock, General physical health deterioration, |
||||
LENALIDOMIDE, |
||||
| 312 | 26501232 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 313 | 26501256 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 314 | 26501500 |
EU |
73 | 1 |
Pneumonia, Psychomotor hyperactivity, Nosocomial infection, Akinesia, Secretion discharge, Contraindicated product administered, Hypokinesia, Decubitus ulcer, Hyperkinesia, Weight decreased, Device issue, Asthenia, Incorrect dose administered, Dyskinesia, Dysarthria, Nasopharyngitis, General physical health deterioration, Underdose, Device use error, Somnolence, Psychomotor hyperactivity, |
||||
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, OXYCODONE, CANDESARTAN, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, PREGABALIN, BISOPROLOL FUMARATE, ROTIGOTINE, AMANTADINE, SIMVASTATIN, OXYCODONE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, SERTRALINE, PANTOPRAZOLE, DARIFENACIN HYDROBROMIDE, MIRTAZAPINE, AMLODIPINE, OXAZEPAM, MAGNESIUM, |
||||
| 315 | 26501550 |
MX |
4 | 2 |
Cardiac disorder, General physical health deterioration, Dehydration, Multiple organ dysfunction syndrome, |
||||
PALIVIZUMAB, PALIVIZUMAB, |
||||
| 316 | 26501788 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 317 | 26501797 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 318 | 26501816 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 319 | 26501817 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 320 | 26501862 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 321 | 26502000 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 322 | 26502055 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 323 | 26502057 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 324 | 26502064 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 325 | 26502076 |
CA |
2 | |
Anti-cyclic citrullinated peptide antibody positive, Abdominal discomfort, Alopecia, Arthralgia, Arthropathy, Blister, Condition aggravated, Confusional state, Contusion, Discomfort, Dyspnoea, Fatigue, Folliculitis, Gastrointestinal disorder, General physical health deterioration, Glossodynia, Drug ineffective, Drug intolerance, Contraindicated product administered, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, RITUXIMAB, RITUXIMAB, LEFLUNOMIDE, LEFLUNOMIDE, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC, DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, OXYCODONE, OXYCODONE, PREDNISOLONE ACETATE, OXYCODONE HYDROCHLORIDE, OXYCODONE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, DICLOFENAC SODIUM, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, HYDROXYCHLOROQUINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, PREDNISONE, APREPITANT, APREPITANT, APREPITANT, APREPITANT, APREPITANT, APREPITANT, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, LEFLUNOMIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CORTISONE ACETATE, CORTISONE ACETATE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, ETANERCEPT, ETANERCEPT, ETANERCEPT, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ALENDRONATE SODIUM, ADALIMUMAB, ADALIMUMAB, ADALIMUMAB, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, ABATACEPT, ABATACEPT, ABATACEPT, ABATACEPT, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, INFLIXIMAB, GOLIMUMAB, USTEKINUMAB, SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, USTEKINUMAB, USTEKINUMAB, TOFACITINIB, TOFACITINIB, TOFACITINIB, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, DEXAMETHASONE SODIUM PHOSPHATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, SULFASALAZINE, SULFASALAZINE, |
||||
| 326 | 26502152 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 327 | 26502754 |
KR |
||
Pleural effusion, General physical health deterioration, |
||||
AMIVANTAMAB-VMJW, |
||||
| 328 | 26502769 |
US |
48 | 2 |
Glioblastoma, Hypophagia, General physical health deterioration, Metastases to spinal cord, Dysphagia, Feeding intolerance, Drug ineffective, |
||||
BEVACIZUMAB, TEMOZOLOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, AMINOLEVULINIC ACID HYDROCHLORIDE, PEMBROLIZUMAB, LENVATINIB, SELINEXOR, |
||||
| 329 | 26497463 |
CA |
69 | |
Death, Fall, Liver disorder, General physical health deterioration, Malaise, Somnolence, Intentional dose omission, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 330 | 26497844 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 331 | 26497864 |
EU |
70 | 1 |
Fall, Speech disorder, Fatigue, General physical health deterioration, Confusional state, Delusion, Hallucination, Urinary tract infection, Memory impairment, On and off phenomenon, Stoma site hypergranulation, Gait disturbance, Nocturia, |
||||
CARBIDOPA AND LEVODOPA, |
||||
| 332 | 26497144 |
EU |
59 | |
Lymphoma, Submandibular gland enlargement, Testicular neoplasm, Dysphonia, Night sweats, Stress, General physical health deterioration, Richter^s syndrome, Dyspnoea, Dyspnoea, Pain in extremity, Off label use, Asthenia, |
||||
VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, |
||||
| 333 | 26497295 |
US |
2 | |
General physical health deterioration, |
||||
TOCILIZUMAB, |
||||
| 334 | 26491957 |
CA |
61 | 2 |
Asthenia, COVID-19, Clostridium difficile colitis, Disturbance in attention, Dyspnoea, Illness, Irregular sleep phase, Malaise, Muscle spasms, Peripheral swelling, Pruritus, Tachycardia, Cataract, Constipation, Diarrhoea, Dysgeusia, General physical health deterioration, Influenza, Liver function test increased, Lymphadenopathy, Nausea, Urinary tract infection bacterial, Pneumonia, Rash pruritic, Sleep disorder, Abdominal discomfort, Somnambulism, Disease progression, Inappropriate schedule of product administration, Product dose omission issue, |
||||
LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, SEMAGLUTIDE, |
||||
| 335 | 26492112 |
JP |
70 | |
General physical health deterioration, Decreased appetite, Vulval neoplasm, Metastases to bone, Hepatomegaly, Ascites, Oedema, Back pain, Pleural effusion, Inhibitory drug interaction, Drug effective for unapproved indication, Intentional product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 336 | 26492270 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 337 | 26492294 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 338 | 26492484 |
CA |
2 | |
General physical health deterioration, Glossodynia, Grip strength decreased, Hand deformity, Headache, Helicobacter infection, Hepatic cirrhosis, Hepatic enzyme increased, Hypercholesterolaemia, Hypersensitivity, Hypertension, Hypoaesthesia, Impaired healing, |
||||
APREMILAST, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, AZATHIOPRINE SODIUM, CALCIUM CARBONATE, ANTACID, CELECOXIB, CERTOLIZUMAB PEGOL, CETIRIZINE HYDROCHLORIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE TABLETS, CHLORHEXIDINE GLUCONATE, ANTISEPTIC SKIN CLEANSER, CERTOLIZUMAB PEGOL, CLONIDINE HYDROCHLORIDE, CORTISONE ACETATE, DESOXIMETASONE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE TABLETS, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, ETANERCEPT, VEDOLIZUMAB, FOLIC ACID, GOLIMUMAB, ADALIMUMAB, HYDROCORTISONE SODIUM SUCCINATE, INFLIXIMAB, ISOPROPYL ALCOHOL, 70%ISOPROPYL ALCOHOL, ALCOHOL PREP PADS, ALCOHOL, ISOPROPYL ALCOHOL SPRAY, MESALAMINE, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, PANTOPRAZOLE, PREGABALIN, QUETIAPINE FUMARATE, QUETIAPINE, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 339 | 26492510 |
US |
||
Malaise, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 340 | 26492512 |
EU |
81 | 2 |
Gait inability, General physical health deterioration, Fall, Tachycardia, Dysuria, Oedema peripheral, Dizziness, |
||||
OLANZAPINE, MIRTAZAPINE, TORSEMIDE, ARIPIPRAZOLE, |
||||
| 341 | 26492686 |
US |
64 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 342 | 26492721 |
EU |
2 | |
General physical health deterioration, Fall, |
||||
CARBOPLATIN, ETOPOSIDE, DURVALUMAB, |
||||
| 343 | 26492790 |
US |
50 | 1 |
General physical health deterioration, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
| 344 | 26492948 |
EU |
1 | |
General physical health deterioration, Dysphagia, |
||||
QUETIAPINE, MIDODRINE HYDROCHLORIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, CITALOPRAM, CITALOPRAM HYDROBROMIDE, |
||||
| 345 | 26493096 |
US |
||
General physical health deterioration, Cognitive disorder, Fatigue, |
||||
OCRELIZUMAB, |
||||
| 346 | 26493373 |
EU |
73 | 1 |
Pneumonia, Decubitus ulcer, Contraindicated product administered, Secretion discharge, Hypokinesia, Asthenia, Nasopharyngitis, Psychomotor hyperactivity, Dyskinesia, Psychomotor hyperactivity, Weight decreased, Dysarthria, Weight decreased, Hyperkinesia, Somnolence, Akinesia, General physical health deterioration, Underdose, Incorrect dose administered, Device use error, Device issue, |
||||
CLINDAMYCIN HYDROCHLORIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AMANTADINE, AMLODIPINE, BISOPROLOL FUMARATE, CANDESARTAN, DARIFENACIN HYDROBROMIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MAGNESIUM, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MIRTAZAPINE, ROTIGOTINE, OXAZEPAM, OXYCODONE, OXYCODONE, PANTOPRAZOLE, PREGABALIN, SERTRALINE, SIMVASTATIN, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, |
||||
| 347 | 26493504 |
TW |
83 | 1 |
Muscular weakness, Eyelid ptosis, Choking, General physical health deterioration, |
||||
NIVOLUMAB, |
||||
| 348 | 26493518 |
CA |
80 | 1 |
Activated partial thromboplastin time prolonged, Anaemia, Analgesic therapy, Antacid therapy, Anticoagulant therapy, Aspiration, Asthenia, Asthma, Bacterial infection, Benign prostatic hyperplasia, Blood calcium increased, Blood creatinine increased, Blood test abnormal, Breath sounds abnormal, Bronchopulmonary aspergillosis allergic, Cardiovascular disorder, Chronic obstructive pulmonary disease, Condition aggravated, Congenital hiatus hernia, Coronary artery disease, Diabetes mellitus, Drug hypersensitivity, Drug intolerance, Drug therapy, End stage renal disease, Fatigue, Full blood count abnormal, Gastrointestinal disorder, General physical health deterioration, Gout, Headache, Hypercholesterolaemia, Hyperlipidaemia, Hyperphosphataemia, Hypertension, Hyponatraemia, Hypophosphataemia, Liver disorder, Lower respiratory tract infection, Lung disorder, Malignant melanoma stage 0, Micturition urgency, Multiple organ dysfunction syndrome, Musculoskeletal stiffness, Myasthenia gravis, Neuralgia, Oedema peripheral, Pain, Pleuritic pain, Pulmonary embolism, Pyrexia, Respiratory symptom, Sepsis, Sleep disorder, Sleep disorder therapy, Somnolence, Stress, Swelling, Thrombosis, Transaminases increased, Transient ischaemic attack, Tremor, Troponin increased, Ulcer, Upper respiratory tract infection, Joint injury, Incorrect route of product administration, Intentional product misuse, Product dose omission issue, Product use in unapproved indication, Off label use, Drug ineffective, |
||||
GABAPENTIN, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ALBUTEROL SULFATE, ALLANTOIN, MEDICINAL MASSAGE OIL, ALLANTOIN, MEDICINAL MASSAGE OIL, ALLOPURINOL, AMIODARONE HYDROCHLORIDE, AMLODIPINE BESYLATE, AMMONIUM CHLORIDE, DARBEPOETIN ALFA, BETAMETHASONE DIPROPIONATE, BIOTIN, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, BISMUTH SUBNITRATE, BUDESONIDE, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, CALCIUM, CANDESARTAN, CEFTRIAXONE SODIUM, CITRIC ACID, HYDROCORTISONE, DEXLANSOPRAZOLE, DEXTROSE MONOHYDRATE, DEXTROSE, DOBUTAMINE HYDROCHLORIDE, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, PSYLLIUM HUSK, FOLIC ACID, FOLIC ACID, DALTEPARIN SODIUM, IPRATROPIUM BROMIDE, NITROGLYCERIN, HEPARIN SODIUM, HORSE CHESTNUT, HYDROMORPHONE HYDROCHLORIDE, INSULIN ASPART, EFINACONAZOLE, EFINACONAZOLE, HYDROMORPHONE HYDROCHLORIDE, LANTHANUM CARBONATE, LANTHANUM CARBONATE, LANTHANUM CARBONATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, INSTALAX POLYETHYLENE GLYCOL 3350, MAGNESIUM CARBONATE, MAGNESIUM OXIDE, MANNITOL, MELATONIN, METRONIDAZOLE, METRONIDAZOLE TOPICAL, METRONIDAZOLE, METRONIDAZOLE TOPICAL, METRONIDAZOLE, METRONIDAZOLE TOPICAL, MONTELUKAST SODIUM, MONTELUKAST, MORPHINE SULFATE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, MOMETASONE FUROATE, NICOTINAMIDE, NITROGLYCERIN, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE BITARTRATE, MEPOLIZUMAB, ONDANSETRON HYDROCHLORIDE, OSELTAMIVIR, OSELTAMIVIR PHOSPHATE, OSELTAMIVIR, OSELTAMIVIR PHOSPHATE, MANNITOL, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PHYTONADIONE, PHYTONADIONE, PHYTONADIONE, PHYTONADIONE, PHYTONADIONE, PHYTONADIONE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, VITAMIN C, POTASSIUM BROMIDE, |
||||
| 349 | 26493705 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 350 | 26493748 |
CN |
23 | 1 |
Critical illness, Pseudomonas infection, Pneumonia, Pneumocystis jirovecii pneumonia, Klebsiella infection, Productive cough, Pneumonitis, Pyrexia, Cough, General physical health deterioration, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, ETOPOSIDE, GENTAMICIN, GENTAMICIN SULFATE, LEUCOVORIN CALCIUM, |
||||
| 351 | 26493971 |
US |
||
Ill-defined disorder, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 352 | 26493973 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 353 | 26494100 |
BR |
65 | 1 |
Heart rate decreased, Fatigue, Product physical issue, Poor quality product administered, General physical health deterioration, |
||||
SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, DAPAGLIFLOZIN, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 354 | 26494448 |
CA |
80 | 1 |
Beta haemolytic streptococcal infection, Fungaemia, Candida infection, Endocarditis, General physical health deterioration, |
||||
EMPAGLIFLOZIN, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, RAMIPRIL, PREGABALIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, LANSOPRAZOLE, ISOSORBIDE MONONITRATE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CLOPIDOGREL, CLOPIDOGREL BISULFATE, ACARBOSE, |
||||
| 355 | 26494473 |
US |
53 | 2 |
Neck pain, Dyspnoea, Throat irritation, General physical health deterioration, Fatigue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TADALAFIL, |
||||
| 356 | 26494837 |
EU |
81 | 2 |
Dysuria, General physical health deterioration, Oedema peripheral, Tachycardia, Gait inability, Fall, Dizziness, |
||||
MIRTAZAPINE, OLANZAPINE, TORSEMIDE, ARIPIPRAZOLE, |
||||
| 357 | 26494945 |
CA |
65 | 2 |
Hypovolaemia, Hypernatraemia, Hypophagia, General physical health deterioration, Hyperglycaemia, |
||||
EMPAGLIFLOZIN, MEMANTINE, MEMANTINE HYDROCHLORIDE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, SITAGLIPTIN, MELATONIN, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, INSTALAX POLYETHYLENE GLYCOL 3350, |
||||
| 358 | 26495054 |
US |
1 | |
Renal impairment, Device related thrombosis, Laboratory test abnormal, General physical health deterioration, |
||||
RAVULIZUMAB, |
||||
| 359 | 26495472 |
CO |
87 | 1 |
Urethral obstruction, General physical health deterioration, Dysstasia, Discomfort, Fall, Lymphoedema, Oedema peripheral, Urinary tract infection, |
||||
ACALABRUTINIB, |
||||
| 360 | 26495543 |
US |
||
Ill-defined disorder, General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 361 | 26495614 |
CA |
44 | 2 |
Abdominal pain, Abdominal pain upper, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Anxiety, Arthralgia, Arthropathy, Asthenia, Asthma, Autoimmune disorder, Blister, Blood cholesterol increased, Bursitis, C-reactive protein abnormal, Chest pain, Condition aggravated, Confusional state, Contraindicated product administered, Contusion, Decreased appetite, Deep vein thrombosis postoperative, Diarrhoea, Discomfort, Dizziness, Drug hypersensitivity, Drug ineffective, Drug intolerance, Dry mouth, Duodenal ulcer perforation, Dyspnoea, Facet joint syndrome, Fatigue, Fibromyalgia, Folliculitis, Gait inability, Gastrointestinal disorder, General physical health deterioration, Glossodynia, Hand deformity, Headache, Helicobacter infection, Hepatic cirrhosis, Hepatic enzyme increased, Hypersensitivity, Hypertension, Hypoaesthesia, Ill-defined disorder, Impaired healing, Infection, Inflammation, Infusion related reaction, Injury, Insomnia, Intentional product use issue, Irritable bowel syndrome, Joint dislocation, Joint range of motion decreased, Joint swelling, Lip dry, Liver disorder, Liver injury, Lower limb fracture, Lower respiratory tract infection, Lung disorder, Malaise, Maternal exposure during pregnancy, Maternal exposure timing unspecified, Mobility decreased, Muscle injury, Muscle spasms, Musculoskeletal pain, Musculoskeletal stiffness, Nasopharyngitis, Night sweats, Obesity, Oedema, Oedema peripheral, Osteoarthritis, Pain, Paraesthesia, Pemphigus, Pericarditis, Peripheral swelling, Peripheral venous disease, Prescribed overdose, Product use in unapproved indication, Product use issue, Pruritus, Psoriatic arthropathy, Pyrexia, Rash, Rheumatic fever, Rheumatoid arthritis, Rheumatoid factor positive, Road traffic accident, Sciatica, Sinusitis, Sleep disorder, Sleep disorder due to general medical condition, insomnia type, Stomatitis, Swelling, Swollen joint count increased, Synovitis, Systemic lupus erythematosus, Therapeutic product effect decreased, Therapy non-responder, Treatment failure, Type 2 diabetes mellitus, Urticaria, Vomiting, Weight increased, Wheezing, Wound, |
||||
TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LORAZEPAM, CAFFEINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LORAZEPAM, ERGOCALCIFEROL, TRIMETHOPRIM, |
||||
| 362 | 26496029 |
CA |
43 | 2 |
Abdominal discomfort, Abdominal pain, Abdominal pain upper, Alopecia, Anti-cyclic citrullinated peptide antibody positive, Arthralgia, Arthropathy, Asthenia, Blister, Blood cholesterol increased, Bursitis, C-reactive protein abnormal, Condition aggravated, Confusional state, Diarrhoea, Discomfort, Dizziness, Dry mouth, Duodenal ulcer perforation, Facet joint syndrome, Fatigue, Fibromyalgia, Folliculitis, General physical health deterioration, Glossodynia, Hand deformity, Helicobacter infection, Hepatic enzyme increased, Hypersensitivity, Impaired healing, Inflammation, Infusion related reaction, Injury, Irritable bowel syndrome, Joint range of motion decreased, Joint swelling, Lip dry, Liver injury, Lower respiratory tract infection, Lung disorder, Muscle injury, Muscle spasms, Musculoskeletal pain, Musculoskeletal stiffness, Nasopharyngitis, Nausea, Night sweats, Obesity, Oedema peripheral, Oedema, Osteoarthritis, Pain, Paraesthesia, Pemphigus, Pericarditis, Peripheral swelling, Peripheral venous disease, Psoriatic arthropathy, Pyrexia, Rash, Rheumatoid arthritis, Rheumatoid factor positive, Stomatitis, Swelling, Synovitis, Systemic lupus erythematosus, Urticaria, Vomiting, Weight increased, Wheezing, Wound, |
||||
SECUKINUMAB, OXYCODONE, RITUXIMAB, DICLOFENAC SODIUM, LEFLUNOMIDE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, PREDNISONE, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, TOCILIZUMAB, CALCIUM CARBONATE, ANTACID, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CERTOLIZUMAB PEGOL, CORTISONE ACETATE, DESOXIMETASONE, DESOXIMETASONE, DESOXIMETASONE, ETANERCEPT, ALENDRONATE SODIUM, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, FOLIC ACID, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE, ADALIMUMAB, INFLIXIMAB, ABATACEPT, ABATACEPT, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, PREDNISONE, PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HCL, TOFACITINIB, VITAMIN C, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, SULFASALAZINE, USTEKINUMAB, GOLIMUMAB, ACETAMINOPHEN AND CODEINE, LORAZEPAM, CAFFEINE, CAFFEINE CITRATE, DESOGESTREL AND ETHINYL ESTRADIOL, DEXPANTHENOL, ERGOCALCIFEROL, ASIAN GINSENG, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LISINOPRIL, LORAZEPAM, LANSOPRAZOLE, PYRIDOXINE HYDROCHLORIDE, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, RAMIPRIL, THIAMINE HYDROCHLORIDE, SULFASALAZINE, VITAMIN A, LISINOPRIL, |
||||
| 363 | 26496437 |
US |
23 | 2 |
Arthralgia, Joint swelling, General physical health deterioration, |
||||
ABATACEPT, |
||||
| 364 | 26496569 |
CA |
36 | 2 |
Fine motor skill dysfunction, Tremor, General physical health deterioration, Sleep disorder, Insomnia, Fatigue, Paraesthesia, Hypoaesthesia, Paraesthesia, Feeling cold, Headache, Nausea, Back pain, Condition aggravated, |
||||
VORASIDENIB, VORASIDENIB, |
||||
| 365 | 26496663 |
US |
77 | 1 |
Neoplasm malignant, General physical health deterioration, |
||||
ADALIMUMAB, |
||||
| 366 | 26500255 |
73 | 1 | |
General physical health deterioration, Spinal stenosis, Cerebrovascular accident, Parkinson^s disease, |
||||
LEVODOPA, |
||||
| 367 | 26500764 |
74 | 2 | |
Infusion related reaction, Superior sagittal sinus thrombosis, Headache, Recalled product administered, General physical health deterioration, Blood pressure fluctuation, |
||||
APIXABAN, RABEPRAZOLE, LOSARTAN, CLONIDINE, HYDRALAZINE HYDROCHLORIDE, PREDNISONE, METHOCARBAMOL, METHOCARBAMOL TABLETS, CYCLOSPORINE, FOLIC ACID, ERGOCALCIFEROL, |
||||
| 368 | 26485356 |
UA |
23 | 2 |
General physical health deterioration, Swelling, Tracheal oedema, Lymphadenopathy, Tracheal haemorrhage, Dermatitis allergic, Neck pain, Tracheal pain, Lymph node pain, Hepatic pain, |
||||
RISDIPLAM, |
||||
| 369 | 26485390 |
CO |
73 | 1 |
Death, Abdominal distension, General physical health deterioration, Chromaturia, Lymphadenopathy, Splenomegaly, |
||||
IBRUTINIB, |
||||
| 370 | 26486957 |
EU |
||
Erythema, Asthenia, General physical health deterioration, Decreased appetite, Pruritus, Angioedema, |
||||
| 371 | 26487030 |
JP |
75 | 2 |
Cataract, General physical health deterioration, |
||||
DUPILUMAB, |
||||
| 372 | 26487143 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 373 | 26487397 |
ID |
40 | 1 |
Death, General physical health deterioration, Asthenia, Back pain, Off label use, |
||||
AXITINIB, PEMBROLIZUMAB, |
||||
| 374 | 26487470 |
EU |
86 | 2 |
Delirium, Oxygen saturation decreased, Urinary retention, Listless, Hyponatraemia, Liver function test increased, Atrial fibrillation, Apathy, Hypokalaemia, Nausea, Confusional state, Hypertension, Vertigo, Head discomfort, Cognitive disorder, Fall, General physical health deterioration, Encephalopathy, Pelvic fracture, Fracture, Hypoacusis, Overdose, Restlessness, Dizziness, Drug interaction, Condition aggravated, Dehydration, Bedridden, Loss of personal independence in daily activities, Discomfort, Anxiety, Poor quality sleep, Contusion, Immobile, Mobility decreased, Medication error, Incorrect dose administered, Affect lability, Mood swings, Reduced facial expression, Foreign body, Sleep disorder, Prescription drug used without a prescription, |
||||
DONEPEZIL HYDROCHLORIDE, AMLODIPINE BESYLATE, PREGABALIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, TELMISARTAN, RAMIPRIL, ROSUVASTATIN, APIXABAN, METHOTREXATE, METHOTREXATE SODIUM, METHOTREXATE, METHOTREXATE SODIUM, AMIODARONE HYDROCHLORIDE, AMLODIPINE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ALPRAZOLAM, ROSUVASTATIN CALCIUM, FENTANYL, FENTANYL, ACETAMINOPHEN, DEXTROMETHORPHAN HBR, ACETAMINOPHEN AND DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN AND PHENYLEPRINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, FOLIC ACID, PREDNISONE, PREDNISONE, PREDNISONE, MELOXICAM, MELOXICAM, METOPROLOL TARTRATE, METOPROLOL, TELMISARTAN, TELMISARTAN, OXAZEPAM, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PREDNISONE, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, CAPTOPRIL, FENTANYL, GUAIFENESIN, MELOXICAM, MELOXICAM, METOPROLOL TARTRATE, METOPROLOL, PANTOPRAZOLE, PANTOPRAZOLE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 375 | 26487869 |
CA |
2 | |
General physical health deterioration, |
||||
CLOZAPINE, |
||||
| 376 | 26487895 |
EU |
20 | 2 |
Somatic hallucination, Somatic hallucination, Hallucination, auditory, Hallucination, auditory, General physical health deterioration, Depressed mood, Hepatosplenomegaly, Gastrointestinal disorder, Malaise, Hypotension, Injection site erythema, Injection site induration, Sedation, Fatigue, Vomiting, Nausea, Incorrect dose administered, |
||||
ARIPIPRAZOLE, ARIPIPRAZOLE, ARIPIPRAZOLE, ARIPIPRAZOLE, ARIPIPRAZOLE, |
||||
| 377 | 26488029 |
US |
78 | 1 |
Rheumatoid arthritis, Pain, General physical health deterioration, |
||||
ABATACEPT, |
||||
| 378 | 26488093 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 379 | 26488409 |
CA |
88 | |
General physical health deterioration, Loss of personal independence in daily activities, Pain, Pain in extremity, Swelling, Oedema peripheral, Overdose, Inappropriate schedule of product administration, Therapeutic product effect decreased, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 380 | 26488503 |
42 | 1 | |
Cerebral haemorrhage, General physical health deterioration, |
||||
EMICIZUMAB, |
||||
| 381 | 26488935 |
EU |
64 | 1 |
General physical health deterioration, Vomiting, |
||||
OXALIPLATIN, DOCETAXEL, DOCETAXEL ANHYDROUS, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 382 | 26489210 |
89 | 2 | |
Cognitive disorder, Mobility decreased, General physical health deterioration, |
||||
MORPHINE, LISINOPRIL, METHYLDOPA, AMLODIPINE, |
||||
| 383 | 26489396 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 DOTATATE, |
||||
| 384 | 26489417 |
US |
||
General physical health deterioration, Insurance issue, |
||||
| 385 | 26489636 |
US |
2 | |
Hospitalisation, General physical health deterioration, |
||||
CILTACABTAGENE AUTOLEUCEL, |
||||
| 386 | 26489676 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 387 | 26490353 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 388 | 26490600 |
US |
1 | |
General physical health deterioration, Product dose omission issue, |
||||
ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, |
||||
| 389 | 26490681 |
US |
44 | 2 |
Pain, General physical health deterioration, |
||||
ABATACEPT, |
||||
| 390 | 26490779 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 391 | 26490884 |
VN |
64 | 2 |
General physical health deterioration, |
||||
OSIMERTINIB, |
||||
| 392 | 26490904 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 393 | 26490983 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 394 | 26491299 |
US |
59 | 2 |
General physical health deterioration, |
||||
ABATACEPT, |
||||
| 395 | 26491568 |
US |
72 | 2 |
General physical health deterioration, Pain, |
||||
ABATACEPT, ABATACEPT, CERTOLIZUMAB PEGOL, |
||||
| 396 | 26491687 |
CN |
73 | 2 |
Inappropriate schedule of product administration, General physical health deterioration, Drug delivery system issue, |
||||
| 397 | 26491754 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 398 | 26491770 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 399 | 26491771 |
US |
||
Drug ineffective, General physical health deterioration, |
||||
NIPOCALIMAB, |
||||
| 400 | 26491785 |
US |
||
General physical health deterioration, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28